People: Immuron Ltd (IMC.AX)

IMC.AX on Australia Stock Exchange

0.01AUD
24 Jul 2014
Price Change (% chg)

$0.00 (+10.00%)
Prev Close
$0.00
Open
$0.00
Day's High
$0.00
Day's Low
$0.00
Volume
717,500
Avg. Vol
2,710,041
52-wk High
$0.02
52-wk Low
$0.00

Search Stocks

Summary

Name Age Since Current Position

Roger Aston

2012 Non-Executive Chairman of the Board

Amos Meltzer

2013 Interim Chief Executive Officer

Grant Rawlin

2011 Chief Scientific Officer

Gerhard Rank

Head - Production and Product Management

Mark Sullivan

Head - Clinical Research Programs

Nina Webster

Head - Commercialization and Intellectual Property

Phillip Hains

2013 Joint Company Secretary

Peter Vaughan

2013 Joint Company Secretary

Daniel Pollock

2012 Director

Stephen Anastasiou

2013 Non-Executive Director

Biographies

Name Description

Roger Aston

Dr. Roger Aston, Ph.D., is Non-Executive Chairman of the Board of Immuron Limited since October 8, 2012. He was appointed Non-Executive Director on May 5, 2012. Within the Company he is Member of Audit and Risks Committee. Dr. Aston has more than 20 years of experience in the pharmaceutical and biotech industries. Dr. Aston was previously the Chief Executive Officer and a Director of Mayne Pharma Group Limited. Prior to his position at Mayne Pharma, some of his previous positions have included CEO of Peptech Limited (Australia), Director of Cambridge Antibody Technology Limited (UK) and Chairman of Cambridge Drug Discovery Limited (UK – now Bio Focus plc). Dr. Aston was also founder and CEO of Biokine Technology Ltd (UK) prior to its acquisition by the Peptech Group. Dr. Aston was also a director of pSivida Ltd. During the past 20 years of his career, Dr. Aston has been closely involved in the development of a number of pharmaceutical and biotechnology companies. Dr. Aston has experience including negotiating global license agreements, overseeing product registration activities with the FDA, the establishment and implementation of guidelines and operating procedures for manufacturing and clinical trials, overseeing manufacturing of human and veterinary products, private and public fund raising activities and the introduction of corporate governance procedures. Other current directorships include IDT Limited.

Amos Meltzer

Mr. Amos Meltzer has been Interim Chief Executive Officer of Immuron Ltd since March 2013. He has played a role in the commercial expansion of a number of biotechnology companies, and brings with him a pharmaceutical partnering and licensing experience required to meet the Company's business objectives.

Grant Rawlin

Dr. Grant Rawlin is Chief Scientific Officer at Immuron Limited since January 17, 2011. He is registered veterinary surgeon and Associate Member of the Australian Pharmaceutical Physicians Association. He is specialist in virology and pathology. Dr. Rawlin brings in epidemiology and risk management policy of infectious diseases in many species, with a particular focus on emergency management of infectious diseases at a national level. These skills were gained while working as the Principal Veterinary Officer with the Commonwealth of Australia. Dr. Rawlin is co-inventor on all Anadis patents lodged after 2002. Dr. Rawlin leads the Anadis science team and manages the Anadis interface with other work groups: University of Melbourne – Microbiology, Monash University, Murdoch Children's Research Institute, Defence Science & Technology Organisation, clinical trial bases, experimental farms and other facilities. Dr. Rawlin has in managing multi-disciplinary technical information to expedite the passage of innovative products through the regulatory process. Dr. Rawlin holds a Bachelor of Science - Veterinary (University of Sydney), and a Bachelor of Veterinary Science (University of Sydney).

Gerhard Rank

Mark Sullivan

Nina Webster

Phillip Hains

Mr. Phillip Hains is Joint Company Secretary of Immuron Ltd since April 19, 2013. Mr. Hains is a Chartered Accountant and specialist in the public company environment. He services the needs of a number of public company boards and related committees as both their Company Secretary and Chief Financial Officer. He has had over 20 years’ experience in providing accounting, administration, compliance and general management services to both ASX and NASDAQ listed companies.

Peter Vaughan

Mr. Peter Vaughan is Joint Company Secretary of Immuron Ltd since April 19, 2013. Mr. Vaughan is also a Chartered Accountant who has worked in the listed company environment for 10 years across a number of industries serving various finance roles, including the roles of Company Secretary and Chief Financial Officer.

Daniel Pollock

Mr. Daniel Pollock is Director of Immuron Ltd since October 11, 2012. He is a lawyer and has commercial experience in new market entries into overseas markets, including USA, as well as cross-national merger and acquisition projects, distribution agreements and corporate start-ups.

Stephen Anastasiou

Mr. Stephen Anastasiou is Non-Executive Director of Immuron Ltd effective May 28, 2013. He holds a Bachelor of Science (Hons), Graduate Diploma in Marketing and a Masters of Business Administration. He has over 20 years’ experience in general management, marketing and strategic planning within the healthcare industry. He is management consultant with KPMG Peat Marwick and Director and shareholder of a number of unlisted private companies.

Basic Compensation

Search Stocks